Baird lowered the firm’s price target on Contineum (CTNM) to $14 from $16 and keeps an Outperform rating on the shares. The firm updated its model following the announcement of the unfortunate trial miss for PIPE-307 RRMS however, the core thesis for 2026 remains unchanged.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM:
- Contineum price target lowered to $22 from $25 at RBC Capital
- Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback
- Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF
- Closing Bell Movers: Elastic down 12% despite beat and raise
- Optimistic Buy Rating for Contineum Therapeutics Amid Promising PIPE-791 Developments